Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequately controlled AD, remain unknow...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Dermatol
Päätekijät: Simpson, Eric L., Paller, Amy S., Siegfried, Elaine C., Boguniewicz, Mark, Sher, Lawrence, Gooderham, Melinda J., Beck, Lisa A., Guttman-Yassky, Emma, Pariser, David, Blauvelt, Andrew, Weisman, Jamie, Lockshin, Benjamin, Hultsch, Thomas, Zhang, Qin, Kamal, Mohamed A., Davis, John D., Akinlade, Bolanle, Staudinger, Heribert, Hamilton, Jennifer D., Graham, Neil M. H., Pirozzi, Gianluca, Gadkari, Abhijit, Eckert, Laurent, Stahl, Neil, Yancopoulos, George D., Ruddy, Marcella, Bansal, Ashish
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2019
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865265/
https://ncbi.nlm.nih.gov/pubmed/31693077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2019.3336
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia